Molecular docking enabled updated screening of the matrix protein VP40 from Ebola virus with millions of compounds in the MCULE database for potential inhibitors.

Autor:	Odhar HA; Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq., Rayshan AM; Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq., Ahjel SW; Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq., Hashim AA; Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq., Albeer AAMA; Department of pharmacy, Al-Zahrawi University College, Karbala, Iraq.
Jazyk:	angličtina
Zdroj:	Bioinformation [Bioinformation] 2019 Oct 08; Vol. 15 (9), pp. 627-632. Date of Electronic Publication: 2019 Oct 08 (Print Publication: 2019).
DOI:	10.6026/97320630015627
Abstrakt:	Ebola virus is known for several outbreaks of hemorrhagic fever in West Africa. This RNA virus is linked to high fatality and easy transmission. Recently, an effective vaccine and a monoclonal antibody cocktail have been introduced to combat Ebola virus infection. The matrix protein VP40 of Ebola virus is a known drug target and it is essential for viral life cycle through participation in RNA transcription as well as for the budding of the mature virus. It is known that residues phenylalanine 125 and arginine 134 of VP40 are involved in the interaction with RNA. Therefore, it is of interest to screen VP40 with millions of compounds at the mcule.com database for potential inhibitors. The output hits were ranked according to their minimum binding energy to matrix protein VP40. We further calculated the pharmacokinetics and toxicology properties for the best five hits using several predictive ADME analysis web tools. We report a candidate lead (compound #5: ((10R)-10-(4-hydroxyphenyl)-11,12,14,16-tetraazatetracyclo[7.7.0.02,7.011,15] hexadeca-1(16), 2(7),3,5,8,12,14-heptaen-8-ol)) with high drug-likeness score, promising lead-likeness behaviour and high median lethal dose. The candidate lead compound #5 engages in hydrogen bonding and hydrophobic interactions with VP40 active site residues. Thus, the lead compound #5 is recommended for further in vitro and in vivo validations for further consideration. (© 2019 Biomedical Informatics.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu